Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now? - Wikidata - wikimedia - TriplyDB

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

http://www.wikidata.org/entity/Q42169289

about

Lenvatinib in Advanced Hepatocellular Carcinoma.

P2860

Q49884642-B2A9FAF4-241A-49C6-A8CC-4E84A4B87EAE

P2860

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

http://www.wikidata.org/entity/Q42169289

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@en

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@nl

type

label

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@en

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@nl

prefLabel

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@en

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@nl

P1433

Q42169289-1670FC0D-8076-4270-A194-571BCCAC0939

P1476

Q42169289-AD713B45-3A2B-44B4-8D3B-8B1805758CE8

P2093

Q42169289-A92FC3EA-51BD-4F0F-ACD3-7F7BF5F23E66

P2860

Q42169289-03F34FB1-D2DB-4A80-9838-9DD2FF356233

Q42169289-0E1D9385-CC29-43BD-8C9D-DE7C4631BA33

Q42169289-1C69E76D-E4D4-4DFB-892E-9AD5BDC1BF10

Q42169289-1E09FBAF-FFEB-451B-86C9-C31F53BF3DF4

Q42169289-289FB2EA-45A7-41B2-9620-7C5993B52A22

Q42169289-28BF7808-C504-4C36-9805-102E7858C3CA

Q42169289-394AB17C-38C5-413D-8B2C-B81A935D01BB

Q42169289-4A719FAF-CF06-4957-96E0-C506D9F49A48

Q42169289-4DE0FB41-141C-4842-96E7-A0D2C1077767

Q42169289-565EFF07-C329-4C60-ABE0-4D6C5531BC09

P304

Q42169289-8B82433B-1110-4FB0-A650-4986325BB6AD

P31

Q42169289-46cfa2e0-115a-4185-999f-77cada49dddf

Q42169289-9E0F75DE-47CB-46FD-BD9D-9AC916E1D771

P356

Q42169289-2B3E7C90-026D-4B23-9BC3-B466F7F91612

P433

Q42169289-37751651-68F0-4436-9C5E-7A4BDD4E11D0

P478

Q42169289-FE3056DC-56F0-483D-BDF1-C642553584F9

P577

Q42169289-FAD7BFFC-7758-4D9C-A8D6-9CD1D2728A55

P698

Q42169289-57688873-6B92-4CFD-B50F-076C461A6360

P932

Q42169289-B2AFE742-A669-469C-B67E-B95BA96A7371

P356

P1433

P1476

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

@en

P2093

M Kudo

http://www.w3.org/2001/XMLSchema#string

P2860

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Local ablation for hepatocellular carcinoma in taiwan

Drug therapy for advanced-stage liver cancer

Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future

Sorafenib in advanced hepatocellular carcinoma

Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

P304

I-VII

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000367753

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26929926

http://www.w3.org/2001/XMLSchema#string

P932

4716409

http://www.w3.org/2001/XMLSchema#string